$FLGT

Xie Jian sold $21K of FLGT

Xie Jian (President and COO) sold 1,201 shares of Fulgent Genetics, Inc. (FLGT) at $17.60 on 2026-05-27.

Original reporting
SEC EDGAR · Xie Jian
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FLGT
Neutral
medium confidence
Mentioned
$FLGT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FLGTNeutralLow
01

Why it matters

The disclosure updates the record of insider activity, but it does not include any new operational, financial, or regulatory information about FLGT.

02

Market read

Traders may note insider selling, but the transaction appears small and lacks additional corroborating catalysts in the text.

03

What to watch

No context is provided on total insider holdings over time, whether other insiders sold, or whether the sale was part of a broader pattern; without that, signal quality is low.

Relevance 3/10Novelty 3/10Timing: Form 4 filed May 28, 2026 (after-hours/close timing not specified).

Background

The article is a SEC Form 4 insider transaction disclosure for Fulgent Genetics, Inc. (FLGT).

Company-level read

Ticker impact

$FLGTNeutralMedium confidence
Context

Fulgent Genetics insider Xie Jian sold 1,201 shares at $17.60 in a Form 4 filed May 28, 2026.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless follow-on selling or new company news emerges.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the article provides transaction size and price but no accompanying corporate or guidance change.

Market effects

Minimal; single insider sale does not change biotech/genetics sector fundamentals.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, taxes, or planned liquidity needs, especially since the filing does not indicate distress or any related company event.

Key entities

  • Fulgent Genetics, Inc.

    Subject of the Form 4 insider sale by its President and COO.

  • Xie Jian

    President and COO who sold 1,201 shares at $17.60.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FLGTMedAI 8/10

Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript

Fulgent Genetics (FLGT) reported Q2 2026 revenue of $85.4M, up 4% year over year and 20% sequentially, driven by Bako Diagnostics and StrataDX integration. Non-GAAP gross margin was 31.3% and Adjusted EBITDA was a $17.1M loss. Full-year revenue guidance was cut to $330M-$340M due to lower collection rates from a billing system transition.

$FLGTMed

Fulgent Reports Second Quarter 2026 Financial Results

Fulgent Genetics, Inc. (FLGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fulgent Reports Second Quarter 2026 Financial Results • Revenue of $85.4 million, growing 20.1% sequentially • GAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of 31.3% • GAAP loss of